Dr. Bauer evaluates a novel anticancer drug against cancer in companion animals
Dr. Annette Sysel addresses United States Congress Humane Bond Caucus
Bauer Research funds a lab-to-leash program to save laboratory dogs lives
Dr. Annette Sysel pioneers a study in dogs and cats to identify cancer biomarkers
The BRF helps fund a lab-to-leash program and participates in providing loving homes to laboratory dogs. Watch the heart-warming videos below of adorable Beagles that have never experienced grass before....
Dr. Sysel presented ground-breaking cancer research on behalf of the BRF at the
2015 American Association for Cancer Research (AACR) Meeting held at the Pennsylvania Convention Center Philadelphia, Pennsylvania. The study was sponsored by the American Kennel Club Canine Health Foundation, Winn Feline Foundation and Blue Buffalo Foundation for Cancer Research.
Refer to AACR site for more details:
Dr. Annette Sysel conducts a study of tumors in dogs and cats to identify cancer biomarkers
Bauer Research Foundation sets its sites on killing COVID-19
Carrying OUT our Mission...
Dr. Bauer conducts the first-ever evaluation of a vitamin B12 analog as a anti-cancer agent in canine companion animals. Read the article published in the scientific journal, Investigational New Drugs and watch the video interview of Buddy's human parents pertaining to Case 2, as described in the article:
On Wednesday, October 21st, 2015,
Dr. Annette Sysel, President and Chief Veterinary Officer of the Bauer Research Foundation www.bauerresearch.org, addresses the United States Congressional Humane Bond Caucus, founded and launched by United States Congressman Gus Bilirakis (R-FL-12) and Congressman Henry Cuellar (D-TX-28). "The mission of this caucus is to strengthen the humane bond between people and animals in working environments, our homes, hospitals, educational settings, the wild, and agriculture," said Congressman Bilirakis. "The bond with animals has defined humanity for thousands of years. Today's event on Capitol Hill showed why it's so important to celebrate this bond." Source: PR Newswire.
Dr. Sysel leads the BRF team in publishing a comparative oncology study which examines biomarkers in dogs and cats which translates to human cancer as well. The study entitled "Immunohistochemical quantification of the cobalamin transport protein, cell surface receptor and Ki-67 in naturally occurring canine and feline malignant tumors and in adjacent normal tissues" was published in the scientific journal Oncotarget (ranked top 6% of oncology journals).
The analysis of the vitamin B12 receptor and transport protein shows remarkable homology, or similarity among dogs, cats and humans which is a rationale to promote similar treatments amongst species.
Read about the use of cobalamin-specific proteins as potential biomarkers to help diagnose, stage and monitor treatment response in cancer which can also be applied to neurologic diseases regarding deficiencies in one-carbon metabolism.